Aridis Pharmaceuticals, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: San Jose CA United States (2003)

Organization Overview

First Clinical Trial
2012
NCT01589185
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Aridis Pharmaceuticals | Aridis Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

medi4893 (1 trial)

tosatoxumab (Salvecin) (1 trial)

Drugs in Phase 2 Trials (4)

Key: Aridis Pharmaceuticals, Inc. (3) Acquired (1)

aerubumab (1 trial)

gallium citrate ga 67 (1 trial)

kbpa-101 (1 trial)

kbsa301 (1 trial)

Drugs in Phase 1 Trials (1)

aerucin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bacterial Infections (Phase 3)

Communicable Diseases (Phase 3)

Cystic Fibrosis (Phase 2)

Fibrosis (Phase 2)

Infections (Phase 3)

Pneumonia (Phase 3)

Pneumonia, Staphylococcal (Phase 2)

Pneumonia, Ventilator-Associated (Phase 3)

Pseudomonas Infections (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 7